RFK Jr. Responds To "Explosion" in Tick-Borne, WEF-Touted Alpha-Gal Syndrome
What they're not telling you: ALPHA-GAL'S SUDDEN EXPLOSION: WHO PROFITS WHEN A TICK DISEASE BECOMES AN EPIDEMIC? Secretary Kennedy's sudden pivot toward alpha-gal syndrome as a priority issue raises a straightforward question that his own HHS has yet to answer: Why is a disease that was medically documented but epidemiologically stable for decades now epidemic enough to warrant "major efforts" on tick control and pharmaceutical development, and who stands to make money when it does? The numbers tell a story the mainstream coverage has ignored.
What the Documents Show
Kennedy claims that 50 percent of Martha's Vineyard's adult population now carries alpha-gal syndrome—a disease caused by the Lone Star tick that triggers severe allergic reactions to mammalian meat proteins. A 50 percent infection rate in an affluent coastal community is not a statistical anomaly. The pharmaceutical companies developing prophylactics and cures, which Kennedy says HHS is now "funding" and "working with," have not been identified. Neither has the dollar amount committed to these studies, nor the commercial terms under which HHS is underwriting private pharmaceutical development. This is the missing data point that matters most: Which pharmaceutical corporations are receiving taxpayer money to monetize what was, until recently, a marginal medical condition?
Follow the Money
The timing warrants scrutiny. Kennedy's announcement coincides with what his own source describes as a "groundswell" of reported tick infestations across farmland. But groundswell attestations on social media are not epidemiological data. The CDC has not released updated prevalence numbers for alpha-gal syndrome. No federal agency has published a timeline showing when the infection rate accelerated or in which geographic zones. We have Kennedy's anecdotal account of Martha's Vineyard and farmers' video posts.
What Else We Know
We do not have: —The names of the pharmaceutical companies involved —The contract amounts HHS has committed —The regulatory pathway these drugs will follow —Whether the drug development was already underway before Kennedy's public announcement —Which regulatory officials at FDA approved or expedited these development programs —The lobbying expenditures, if any, made by those companies in the prior 24 months Kennedy's mention of "strategies for eliminating breeding capacity" of Lone Star ticks through deer population management introduces another opaque pathway for corporate benefit. Pest control contracts, wildlife management services, and pharmaceutical tick-control products would all represent downstream revenue streams activated by federal mandate. No disclosure of who bids for these programs or what they've historically donated to political figures or causes. The pattern here is institutional: a disease gains sudden political salience, a federal agency announces urgency, pharmaceutical and services companies benefit from taxpayer-funded development and implementation, and the media reports the public health framing without asking who specifically profits or what those profit margins are. Kennedy's involvement adds credibility to the public health narrative, but credibility and transparency are not identical. A former SEC examiner knows the difference.
What strikes me about this story is that nobody in the mainstream coverage asked the most basic question a securities examiner would ask: follow the money. When a disease suddenly becomes a federal priority requiring pharmaceutical development and large-scale pest control intervention, the first conversation should be about who gets the contracts and the taxpayer funding, not whether the disease is real or urgent.
The pattern I've observed repeatedly in regulatory capture is that the government agency's framing of the problem becomes inseparable from the solutions available to private vendors. HHS identifies alpha-gal as an "explosion." HHS then funds companies to develop drugs and deploy services to manage it. Those companies benefit materially. The public narrative becomes the justification for the expenditure. Nobody reports the conflict.
What's structurally wrong here is the opacity. Kennedy's commitment to addressing alpha-gal may be entirely genuine and epidemiologically sound. But institutional credibility depends on transparency—on naming the companies, publishing the contract terms, and disclosing whether those companies have lobbying access to the officials approving the deals.
What readers should demand: the complete list of pharmaceutical and pest control contractors receiving HHS funding related to alpha-gal, the contract amounts, and the prior 18 months of lobbying disclosures for those companies. That data should be public within 30 days. If it isn't, ask why.
Primary Sources
- Source: ZeroHedge
- Category: Corporate Watchdog
- Cross-reference independently — don't take our word for it.
Disclosure: NewsAnarchist aggregates from public records, API feeds (Federal Register, CourtListener, MuckRock, Hacker News), and independent media. AI-assisted synthesis. Always verify primary sources linked above.